RNA Supply Chain Videos

1. Addressing Industry Challenges In mRNA Product Commercialization

   While the speed of production and flexibility of mRNA are appealing, several industry challenges must still be addressed to realize the full potential and further expand its use.

2. The Make-or-Break Quality Attributes of Plasmid DNA 10/15/2025

   We all know that plasmid quality is foundational in dictating the quality of the final mRNA drug substance. In this clip homing in on upstream process considerations, speakers Stu Sundseth (Tune Therapeutics), Marc Wolfgang (Sail Biomedicines), and Christian Dohmen (Ethris) outline some of the most important CQAs for plasmids and the impact they can have on the resulting quality of the mRNA drug substance for linear mRNA. 

3. Primates, Patents, And Progress: Advancements In Rational LNP Design 2/24/2026

   In this opening Advancing RNA Live clip, NanoVation Therapeutics’ Dominik Witzigmann and Stealth Co’s John Zuris share the scientific advancements they’ve been watching most keenly in the LNP space, as well as some of the evolutions they’re seeing in the overall quality of our RNA-LNP products.

4. Can A Small Plasmid Produce Huge Benefits? The Power Of Small 1/17/2023

   With benefits across applications, nanoplasmids are designed to replace antiquated bacterial backbones, while eliminating antibiotic markers that can cause regulatory concerns.

5. The Evolving CMC Landscape For mRNA-LNPs 2/24/2026

   In this Advancing RNA Live clip, CMC consultant Sujit Jain unpacks the levels of maturity he’s observed in process and analytical development, as well as supply chain. While vaccines and liver-targeting therapeutics boast what we can call a reproducible platform today, targeted LNP therapies introduce a handful of scale-up sensitivities and characterization hurdles.

6. mRNA Raw Material Pulse Check: Where Innovation Is Hottest 12/3/2025

   The mRNA supply chain is undergoing massive growth in three particular areas. Here, speakers Khaled Yamout & Francoise Ribes walk us through the materials that have undergone the most scientific growth over the past few years and the impacts they’re noting these advancements having on the development of our mRNA drug substances and mRNA-LNP drug products. 

7. What Does 2025 (And Beyond) Hold For The RNA-LNP Space? 12/4/2024

   Three LNP experts share their thoughts on the incremental advancements they’d like to see the RNA-LNP space make in the next few years.

8. Beyond Solid Phase: Weighing Supply Chain Readiness For Liquid Phase & Hybrid Oligo Synthesis 12/3/2025

   The oligo manufacturing paradigm is facing several different evolutions whether it be the transition to liquid-phase or hybrid synthesis. In this Advancing RNA Live clip, Camp4’s Satya Kuchimanchi explores how these manufacturing advancements are impacting our supply chain needs.

9. The State of the Linear mRNA Supply Chain—In Brief

   In this clip, Sanofi’s Greg Troiano kickstarts our discussion on some of the advances he’s seen in the supply chain for linear mRNA-LNP products, both in terms of supply availability and supplier capability.

10. The Strategic Shift(s) In gRNA CMC 4/29/2026

    In this opening Advancing RNA Live clip, panelists Max De Long, April Sena, and Venkat Krishnamurthy share the biggest scientific and manufacturing breakthrough made in the world of gRNA production over the past year.